HUMA: Humacyte Inc P/E Multiple

Corporate emblem and logo of Humacyte Corp (HUMA)

The regenerative medicine sector operates independently of global economic fluctuations, serving as a stable defensive asset due to the constant interest in scientific research. This PE chart for Humacyte, Inc. (HUMA) captured a metric of -1.30, while tissue engineering requires strict sterility and the automation of bioreactors under expert supervision. Humacyte, Inc. (HUMA) supplies finished bioengineered arteries to dialysis centers, replacing synthetics with living structures.

Price to Earnings Ratio: Humacyte Inc. (HUMA) for 07/04/2022 - 11/10/2026

Analytical breakdowns for Humacyte, Inc.

- current price and projected stock value:
Share Price humacyte.com|HUMA - Consensus Target
- market capitalization information:
Market Capitalization Humacyte, Inc.|HUMA - Enterprise Value
- company book value details:
Accounting Value per Share Humacyte|HUMA - Company Net Assets|Market Cap to Book Value Multiple humacyte.com|HUMA - Company Total Assets
- debt and solvency information:
Total Debt to Capital Coefficient Humacyte, Inc.|HUMA - Long-Term Debt to Equity|Current Liabilities to Capital Humacyte Inc.|HUMA - Company Debts|Debt to Book Value Ratio Humacyte, Inc.|HUMA - Company Long-Term Debts|Company Short-Term Loans and Borrowings Humacyte|Quick Ratio humacyte.com
- company profitability and valuation multiples indicators:
HUMA - Company Net Income|Future Profit Humacyte, Inc.|HUMA - P/E Multiple|Forward P/E Multiple Humacyte Inc|HUMA - PEG Multiple|Enterprise Value to EBITDA Ratio Humacyte, Inc.|HUMA - Operating profit before deduction of amortization|Net earnings per one share for the last twelve months Humacyte|HUMA - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months humacyte.com|HUMA - Earnings growth in current year|Expected net earnings per share growth next year Humacyte, Inc.
Comprehensive company analysis:humacyte.com HUMA
Manufactured product of Humacyte

The integration of HAV bioengineered implants into the hospital practice of Humacyte, Inc. (HUMA) creates high switching costs, which is reflected in the current P/E valuation level. This ratio compares the market price of the share with net profit, determining the investment payback period. The calculation is based on the price-to-earnings per share ratio, measuring the premium paid for future growth. This allows for an assessment of capital stability relative to the issuer's fundamental earnings.

Key competitors

Price to Earnings Multiple NTRA (natera.com)|Price to Earnings Ratio SERA (Sera Prognostics)